Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 157 shares of the business’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $64.00, for a total value of $10,048.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Shares of Foundation Medicine Inc (FMI) traded down $0.95 during trading hours on Friday, hitting $68.70. The stock had a trading volume of 398,900 shares, compared to its average volume of 300,737. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.24 and a quick ratio of 2.03. The company has a market cap of $2,440.00, a price-to-earnings ratio of -15.37 and a beta of -0.01. Foundation Medicine Inc has a 12-month low of $17.50 and a 12-month high of $74.30.
Foundation Medicine (NASDAQ:FMI) last posted its quarterly earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share for the quarter, topping the consensus estimate of ($1.06) by $0.16. The company had revenue of $42.66 million for the quarter, compared to the consensus estimate of $37.99 million. Foundation Medicine had a negative return on equity of 143.18% and a negative net margin of 119.69%. The firm’s quarterly revenue was up 45.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.90) EPS. analysts forecast that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.
A number of equities research analysts have recently weighed in on FMI shares. BidaskClub lowered Foundation Medicine from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Zacks Investment Research lowered Foundation Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd. One research analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $45.33.
Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in shares of Foundation Medicine by 8.2% in the 2nd quarter. Vanguard Group Inc. now owns 631,339 shares of the company’s stock worth $25,096,000 after buying an additional 47,843 shares during the last quarter. Peregrine Capital Management LLC purchased a new stake in shares of Foundation Medicine in the 3rd quarter worth approximately $13,299,000. TIAA CREF Investment Management LLC grew its stake in shares of Foundation Medicine by 9.8% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 39,000 shares of the company’s stock worth $1,550,000 after buying an additional 3,490 shares during the last quarter. Macquarie Group Ltd. grew its stake in shares of Foundation Medicine by 33.3% in the 3rd quarter. Macquarie Group Ltd. now owns 106,603 shares of the company’s stock worth $4,285,000 after buying an additional 26,603 shares during the last quarter. Finally, Northern Trust Corp grew its stake in shares of Foundation Medicine by 7.4% in the 2nd quarter. Northern Trust Corp now owns 187,714 shares of the company’s stock worth $7,462,000 after buying an additional 12,881 shares during the last quarter. Institutional investors own 32.68% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This article was first published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://ledgergazette.com/2018/01/12/steven-j-kafka-sells-157-shares-of-foundation-medicine-inc-fmi-stock.html.
Foundation Medicine Company Profile
Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.
Receive News & Ratings for Foundation Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine and related companies with MarketBeat.com's FREE daily email newsletter.